Mannatech Reports Q1 Profit & Positive Cash Flow Amidst Delisting Threat, Extends Insider Debt
summarizeSummary
Mannatech reported a significant Q1 2026 financial turnaround with a net profit and positive operating cash flow, despite declining sales, as it works to address a Nasdaq delisting threat and 'going concern' warning through cost cuts and debt extensions.
check_boxKey Events
-
Swing to Profitability
The company reported a net income of $1.0 million ($0.49 EPS) for Q1 2026, a significant improvement from a net loss of $1.5 million ($0.80 loss per share) in Q1 2025.
-
Positive Operating Cash Flow
Net cash provided by operating activities was $1.1 million in Q1 2026, a substantial turnaround from $1.4 million cash used in Q1 2025. Cash and cash equivalents increased to $7.0 million from $6.2 million at year-end 2025.
-
Continued Sales Decline
Net sales decreased by 6.2% to $24.9 million in Q1 2026 from $26.6 million in Q1 2025, indicating ongoing revenue challenges.
-
Ongoing Nasdaq Delisting Threat & Negative Equity
Shareholders' equity remains negative at ($5.554 million) as of March 31, 2026, worsening slightly from ($5.223 million) at December 31, 2025. The company reiterated its 'going concern' warning and acknowledged the Nasdaq delisting notice received on April 20, 2026, for failing to meet minimum stockholders' equity requirements.
auto_awesomeAnalysis
Mannatech's Q1 2026 results show a significant operational turnaround, posting a net income of $1.0 million and positive cash flow from operations of $1.1 million, a stark improvement from a $1.5 million net loss and negative cash flow in Q1 2025. This positive shift is critical as the company faces a Nasdaq delisting notice due to negative shareholders' equity and has an ongoing 'going concern' warning. While net sales declined by 6.2%, management's aggressive cost-cutting measures, including converting director compensation to equity and headcount reductions, along with the extension of $2.75 million in related-party debt, are crucial steps to improve liquidity and address the company's distressed financial state. The ability to generate profit and cash flow is a strong signal of progress in navigating its severe challenges.
At the time of this filing, MTEX was trading at $4.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.9M. The 52-week trading range was $4.28 to $12.45. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.